<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421226</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885A1101</org_study_id>
    <nct_id>NCT00421226</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Demonstrate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered as Intravenous Infusion and Subcutaneous Injection in Japanese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of&#xD;
      ACZ885 administered via intravenous infusion and subcutaneous injection in healthy Japanese&#xD;
      male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACZ885</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese healthy male subjects age 20 to 45 years of age, and in good health&#xD;
&#xD;
          -  At screening and baseline, the subjects must be in good health as determined by past&#xD;
             medical history, physical examination, electrocardiogram, laboratory tests and&#xD;
             urinalysis.&#xD;
&#xD;
          -  Body mass index within the range of 18 to 28 kg/m2 and weigh 50 to 100 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers.&#xD;
&#xD;
          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter&#xD;
             medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to&#xD;
             dosing. Acetaminophen is acceptable. Treatment of any biologics within three months&#xD;
             prior to dosing. Having live vaccinations within six months prior to dosing.&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 months prior to dosing.&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood within 3 months; donation or loss of 200&#xD;
             mL or more of blood within 1 month; or donation of component blood within 2 weeks&#xD;
             prior to participation.&#xD;
&#xD;
          -  Significant illness (sinusitis, pneumonia, cystitis, sepsis, etc) within two weeks&#xD;
             prior to dosing.&#xD;
&#xD;
          -  A past personal or close family medical history of cardiac disorders&#xD;
&#xD;
          -  History of:&#xD;
&#xD;
               -  fainting,&#xD;
&#xD;
               -  low blood pressure when standing,&#xD;
&#xD;
               -  abnormal heart rhythms&#xD;
&#xD;
               -  acute or chronic bronchospastic disease (including asthma and chronic obstructive&#xD;
                  pulmonary disease, treated or not treated).&#xD;
&#xD;
          -  Clinically significant drug allergy or history and complication of atopic allergy&#xD;
             (asthma, urticaria, eczematous dermatitis)&#xD;
&#xD;
          -  Known hypersensitivity to the study drug or similar drugs&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of drugs or jeopardize participation in the&#xD;
             study.&#xD;
&#xD;
          -  History of immunodeficiency diseases, including a positive HIV test result.&#xD;
&#xD;
          -  A positive Hepatitis B surface antigen (HBsAg), Hepatitis C or Syphilis test result.&#xD;
&#xD;
          -  Drug or alcohol abuse within the 12 months prior to dosing&#xD;
&#xD;
          -  Tuberculosis symptoms, complication of tuberculosis, contact with patients with&#xD;
             suspected tuberculosis symptoms&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>April 27, 2012</last_update_submitted>
  <last_update_submitted_qc>April 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety, tolerability, pharmacokinetics, pharmacodynamics, ACZ885, Japanese,</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

